Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP‐305, a novel farnesoid X receptor agonist

Derek J. Erstad, Christian T. Farrar, Sarani Ghoshal, Ricard Masia, Diego S. Ferreira, Yin‐Ching Iris Chen, Ji‐Kyung Choi, Lan Wei, Phillip A. Waghorn, Nicholas J. Rotile, Chuantao Tu, Katherine A. Graham‐O'Regan, Mozhdeh Sojoodi, Shen Li, Yang Li, Guogiang Wang, Kathleen E. Corey, Yat Sun Or, Lijuan Jiang, Kenneth K. Tanabe, Peter Caravan, Bryan C. Fuchs – 21 May 2018 – We examined a novel farnesoid X receptor agonist, EDP‐305, for its antifibrotic effect in bile duct ligation (BDL) and choline‐deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD) models of hepatic injury.

MicroRNA‐26‐5p functions as a new inhibitor of hepatoblastoma by repressing lin‐28 homolog B and aurora kinase a expression

Yutong Zhang, Yulan Zhao, Jianguo Wu, Suthat Liangpunsakul, Junqi Niu, Li Wang – 21 May 2018 – Hepatoblastoma (HB) is the most common liver tumor in children. Despite recent improvements in treatment strategies, the survival of children with hepatoblastoma remains poor. In this study, we identified a novel role of microRNA‐26a‐5p (miR‐26a‐5p), lin‐28 homolog B (LIN28B), Ras‐related nuclear protein (RAN), and aurora kinase A (AURKA) in HB. The expression of LIN28B, RAN, and AURKA was significantly up‐regulated in human HB livers and cell lines.

Subscribe to